Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Integra LifeSciences Holdings Corporation (IART) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Integra’s Form 8-K filings and related exhibits offer insight into its financial reporting practices, governance programs, and key operational updates as a global medical technology company focused on neurosurgery and tissue reconstruction.
Recent Form 8-K filings include results of operations and financial condition for specific quarters, where Integra furnishes press releases detailing revenues, segment performance for Codman Specialty Surgical and Tissue Technologies, and reconciliations between GAAP and non-GAAP measures. These filings explain how management uses metrics such as organic revenues, adjusted EBITDA, adjusted net income, adjusted gross margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion to evaluate performance and compare results over time.
Other 8-K filings address governance and executive programs, such as a change in control severance program for certain executives. That program, as described in the filing, outlines severance payments, bonus treatment, COBRA premium subsidies, outplacement services, and potential adjustments for excise tax exposure in connection with qualifying terminations following a change in control, with a defined term and renewal provisions overseen by the Board’s Compensation Committee.
Through this filings page, users can review how Integra discusses topics such as quality and compliance initiatives, manufacturing transitions, and the financial impact of structural optimization, acquisition and divestiture-related charges, EU Medical Device Regulation costs, recall-related charges, and impairment charges. Stock Titan enhances access to these documents with AI-powered summaries that help explain technical sections of 10-Ks, 10-Qs, and 8-Ks, highlight key adjustments and definitions, and surface important trends without replacing the underlying filings.
Filings are updated in near real time from the SEC’s EDGAR system, and users can also monitor items related to executive compensation structures and other governance matters. For investors analyzing IART, this page serves as a focused entry point into Integra’s official regulatory record, with tools to interpret complex disclosures more efficiently.
Integra LifeSciences Holdings Corporation files its Annual Report describing a global medical technology business focused on neurosurgery, surgical instruments, ENT and regenerative tissue products. The Codman Specialty Surgical segment provides about 70% of revenue, with Tissue Technologies contributing about 30%.
The company highlights its leadership in neurosurgery, advanced wound care and soft-tissue reconstruction, supported by a broad R&D program and global sales network. It is pursuing PMA approvals for SurgiMend and DuraSorb in breast reconstruction, targeted for 2026, and is relocating and expanding manufacturing capacity, including a new Braintree, Massachusetts facility.
Integra outlines extensive quality and regulatory initiatives, including a Compliance Master Plan to upgrade its quality management systems and respond to FDA expectations. The report also details competitive dynamics, reimbursement and healthcare reform pressures, and comprehensive global regulatory and data privacy obligations. As of June 30, 2025, non‑affiliate market value was about $925.1 million, with 77,937,208 common shares outstanding as of February 25, 2026.
Integra LifeSciences reported flat-to-modest growth in 2025 but a large GAAP loss driven by non-cash charges. Full-year revenue was $1,635.2 million, up 1.5%, while GAAP earnings per diluted share fell to $(6.74) from $(0.09), mainly due to a $511 million goodwill impairment recorded in the second quarter.
On an adjusted basis, 2025 EBITDA was $317.5 million (19.4% margin), slightly below 2024, and adjusted earnings per diluted share declined to $2.23 from $2.56. Free cash flow for the year was negative at $(31.1) million, and net debt stood at $1.60 billion with a total leverage ratio of 4.5x and liquidity of about $516 million.
In the fourth quarter, revenue was $434.9 million, down 1.7%, with organic revenue down 2.5%. GAAP EPS was $(0.02), and adjusted EPS was $0.83. For 2026, the company guides revenue to $1,662–$1,702 million and adjusted EPS to $2.30–$2.40, with Q1 revenue of $375–$390 million and adjusted EPS of $0.37–$0.45.
Integra LifeSciences Holdings Corp received an amended ownership report from institutional investor Fuller & Thaler Asset Management, Inc. as of 12/31/2025. Fuller & Thaler reports beneficial ownership of 3,636,359.96 shares of Integra common stock, representing 4.67% of the class.
The firm has sole power to vote 3,583,652.96 shares and sole power to dispose of 3,636,359.96 shares, with no shared voting or dispositive power. Fuller & Thaler certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Integra.
Integra LifeSciences Holdings Corp reported an equity grant to executive officer Michael Damon Hutchinson, EVP, Chief Legal Officer & Secretary. On 02/02/2026, he received 89,606 restricted stock units at a price of $0 per unit, held as a direct interest.
The filing states that this restricted stock unit award will vest 100% on the second anniversary of the grant date of 02/02/2026, meaning the award is fully time‑based and contingent on continued service through that future vesting date.
Integra LifeSciences Holdings Corp executive Michael Damon Hutchinson filed an initial ownership report showing no securities beneficially owned. The Form 3 identifies him as EVP, Chief Legal Officer and Secretary of Integra LifeSciences, and confirms that, as of the event date, he did not hold any direct or indirect equity or derivative securities of the company.
Integra LifeSciences Holdings Corp President & CEO Mojdeh Poul reported routine equity compensation activity. On January 6, 2026, 848 and 542 shares of common stock were acquired at $0 per share upon the vesting and settlement of corresponding restricted stock units.
On the same date, 848 and 542 common shares were disposed of at $13.13 per share in transactions coded "F", reflecting shares withheld or sold to cover taxes. Following these transactions, the report shows no directly held common stock, while Ms. Poul continues to hold restricted stock unit awards, with post-transaction amounts reported as 102,840 and 102,298 units in two separate grants. A footnote explains that these awards vest in three equal annual installments starting January 6, 2026 and are scheduled for deferred delivery after her separation from service.
Integra LifeSciences Holdings Corporation adopted a renewed change in control severance program for certain senior executives, effective January 1, 2026. The program applies if an executive is terminated without cause or resigns for good reason within two years after a change in control that occurs by December 31, 2026.
Covered leaders include CFO Lea Knight and business presidents Robert T. Davis, Jr., Michael McBreen, and Harvinder Singh. On a qualifying termination, they may receive a lump sum of 1.5 times their salary plus target bonus, or 2 times for Ms. Knight, a pro rata target bonus for the year of termination, subsidized COBRA premiums for up to 18 months, up to 12 months of outplacement services, and any earned but unpaid prior-year bonus. Benefits require a release of claims and are subject to a “best pay cap” that can reduce payments to mitigate excise taxes. The program runs through December 31, 2026, with automatic extensions after a change in control or qualifying termination until all obligations are met.
Integra LifeSciences (IART) director Jeffrey Alan Graves reported an open‑market purchase of 9,000 shares on 11/05/2025 at $11.35 per share.
Following the transaction, he beneficially owns 41,086 shares, held directly. The report was filed as a Form 4 and signed by an attorney‑in‑fact.
Integra LifeSciences (IART) reported Q3 2025 results. Net revenue was $402,062, up from $380,834 a year ago. Operating income was $11,761 versus a loss in the prior year quarter, while net loss narrowed to $5,404 from $10,695.
Year to date, results reflect a non‑cash goodwill impairment of $511,365 recorded in Q2, driving a nine‑month net loss of $514,770. Segment mix showed strength in Codman Specialty Surgical at $292,583, led by Neurosurgery $201,563 and ENT $40,869; Tissue Technologies was $109,479.
On the balance sheet, cash and cash equivalents were $232,186 as of September 30, 2025. The company repaid convertible debt during the period, with “Convertible securities” at $0 versus $573,170 at year‑end, and long‑term borrowings under the senior credit facility rose to $1,708,851. Inventories increased to $489,106. Cash from operations for the nine months was $38,568. Shares outstanding were 77,892,111 as of October 29, 2025.
Integra LifeSciences (IART) furnished an update on results for the quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The release includes reconciliations between GAAP and non-GAAP measures such as organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion for comparable periods in 2025 and 2024.
The company also provided forward-looking guidance for adjusted earnings per diluted share and did not reconcile it to GAAP EPS because certain expense items are highly variable and not reasonably predictable. Non-GAAP adjustments may include structural optimization, acquisition/divestiture and integration-related costs, EU Medical Device Regulation costs, charges related to the prior Boston manufacturing recall and Braintree transition, intangible amortization, tax effects of adjustments, and impairment charges.